Oberland Capital Management

Oberland Capital is a private investment firm focused on providing structured financing solutions to companies within the global healthcare industry. They aim to accelerate the development and commercialization of promising healthcare products, creating value for their partners and improving patient care. Oberland Capital specializes in flexible investment structures tailored to the specific needs of its partners, including monetization of royalty streams, acquisition of future product revenues, project-based financing, and traditional debt and equity investments. The firm employs a fundamental, research-driven approach coupled with quantitative methods to identify and invest in innovative technologies. They focus on investing in pharmaceutical, biotechnology, medical device, and diagnostic companies, partnering with public and private entities, research institutions, and individual inventors. Oberland Capital works collaboratively with management teams to develop creative structures that meet their strategic and financial objectives, providing access to significant capital for various purposes, such as accelerating R&D, expanding commercial infrastructure, acquiring new assets, and refinancing existing capital sources. Oberland Capital distinguishes itself through its flexible investment structures, global transactional experience, and deep domain expertise. They have substantial experience in local legal, tax, and accounting frameworks, enabling them to deploy innovative structures tailored to each geography. The team's scientific, operational, and financial expertise allows them to design creative capital solutions that address the complexities of product development and commercialization across the life sciences sector. They offer meaningful scale, providing partners with $50 million to $300+ million to accelerate organic and inorganic growth opportunities. The firm’s investment strategy focuses on near-commercial stage biopharmaceutical companies with highly differentiated products and deep clinical pipelines, as well as companies with strong commercial products. They have a track record of creating value for their partners through their flexible investment structures and deep healthcare expertise.

pharmaceuticals, biotechnology, medical devices, diagnostics

Core thematic spaces, technologies, and target market segments of interest.